Phil Gingrey: “This law, in my opinion, picks winner and losers.”

I really have to commend the FDA on that and realizing the desire and need for new antibiotics and acting quickly to implement the program.

An overly restrictive regulatory process will stifle innovation and ultimately lead to erosion in the quality of care.

I thank Jim for yielding some of his time. Primarily, I will report on the Congressional Study Groups program. As a Member, I had the honor of co-chairing the Congressional Study Group on Germany for, I think, 4 years. It was absolutely…

there is nothing more permanent than a temporary federal government program.